{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:04:33Z","timestamp":1768417473967,"version":"3.49.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0215783","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:30:32Z","timestamp":1557941432000},"page":"e0215783","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["SVR12 rates higher than 99% after sofosbuvir\/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-3555","authenticated-orcid":true,"given":"Alessandra","family":"Mangia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Piazzolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egidio","family":"Visaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Minerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Carraturo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Lauletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Tagarielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Piccigallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"De Gioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cuccorese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Metrangolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Agostinacchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mennea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Sabb\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggiero","family":"Losappio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"ref1","article-title":"Global health sector strategy on viral hepatitis, 2016\u20132021: towards ending viral hepatitis","year":"2016","journal-title":"Global health sector strategy on viral hepatitis, 2016\u20132021: towards ending viral hepatitis"},{"key":"ref2","unstructured":"EPCLUSA, Gilead Sciences Inc.EPCLUSA (sofosbuvir and velpatasvir) tablets for oral use. US prescribing information Foster City, CA. Revised: August 2017"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"JJ Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"G Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","unstructured":"AASLD\/IDSA. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/hcvguidelines.org.\/Accessed\" xlink:type=\"simple\">https:\/\/hcvguidelines.org.\/Accessed<\/ext-link> 15 March, 2018"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"European Association for the Study of the Liver. EASL recommendations on the treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S716","DOI":"10.1016\/S0168-8278(17)31916-5","article-title":"Safety and efficacy of velpatasvir and sofosbuvir-based regimens for the treatment of HCV genotype 1\u20136: results of the HCV- TARGET study","volume":"66","author":"M Khalili","year":"2017","journal-title":"J Hepatic"},{"key":"ref8","article-title":"Real-World patterns of therapy utilization and outcomes in 8,049 patients:data from the TRIO network","author":"SL Flamm","year":"2017","journal-title":"AASLD"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1016\/S0168-8278(16)01456-2","article-title":"Comorbidities, co-medication and potential drug-to-drug interactions in chronic hepatitis C patients: implications for adequate HCV treatment selection","volume":"64","author":"A Sicras","year":"2016","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"R Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"J Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref12","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","author":"J Vermeheren","year":"2018","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2016.10.012","article-title":"Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology","volume":"38","author":"T Stroffolini","year":"2017","journal-title":"Eur J Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S1090","DOI":"10.1016\/S0016-5085(17)33673-9","article-title":"Real-world results in the Reinassance of HCV care: analyses of treatment for 7550 patients from the TRIO network","volume":"152","author":"S Flamm","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"ref15","first-page":"S736","article-title":"Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1\u20136","volume":"66","author":"CS Landis","year":"2017","journal-title":"Results of HCV TARGET Study Hepatology"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"S726","DOI":"10.1016\/S0168-8278(17)31938-4","article-title":"Utilization of DAA therapies ledipasvir sofosbuvir and sofosbuvir\/velpatasvir in patients with genotype 1 HCV: real world experience from the TRIO","volume":"66","author":"N Tsai","year":"2017","journal-title":"NetworkJ Hepatic"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"PY Kwo","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0168-8278(18)30290-3","article-title":"First real-world data on safety and effectiveness of glecaprevi\/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German Hepatitis C-registry","volume":"68","author":"T Berg","year":"2018","journal-title":"J Hepatol"},{"key":"ref19","article-title":"Real-life effectiveness and safety of Glecaprevir\/Pibrentasvir in 723 patients with chronic hepatitis C","author":"R D\u2019Ambrosio","year":"2018","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1\u20136 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"T Asleep","year":"2018","journal-title":"Liver Intern"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/Velpatasvir: a review in chronic hepatitis C","volume":"76","author":"SL Greig","year":"2016","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Gane E et al Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"GJ Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"J Lalezari","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1016\/S0168-8278(18)30870-5","article-title":"Has increased rollout of direct antiviral therapy decreased the burden of late presentation of advanced liver disease in patients starting Hepatitis C virus therapy in Germany?","volume":"68","author":"JK Rockstroh","year":"2018","journal-title":"J Hepatol"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and Safety of Sofosbuvir\/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL","volume":"63","author":"J Grebely","year":"2016","journal-title":"Trials Clin Inf Dis"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0168-8278(18)30322-2","article-title":"Collocation of buprenorphine with HCV treatment to improve adherence and reduce Harm in PWID with HCV preliminary data from the Anchor Study","volume":"68","author":"E Rosenthal","year":"2018","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"C Rossi","year":"2018","journal-title":"J Hepatol"},{"key":"ref29","first-page":"S1","article-title":"Direct acting antiviral HCV therapy is safe and effective in patients with decompensated cirrhosis: real world experience from the HCV-TARGET cohort","volume":"67","author":"EC Verna","year":"2018","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0223287","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0215783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T02:27:05Z","timestamp":1663468025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0215783"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0215783","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0223287","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}